Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Forbes: Dual-track development in the crypto market, hybrid models of CEX and DEX will become mainstream

Forbes: Dual-track development in the crypto market, hybrid models of CEX and DEX will become mainstream

ChaincatcherChaincatcher2025/12/01 11:38
Show original

ChainCatcher news, according to Forbes, CEX spot and derivatives trading volume surged to $9.72 trillion in August, reaching a new annual high; major exchanges' annual trading volume reached $80 trillion.

The market is showing a dual-track development: CEX attracts institutions and retail investors with high liquidity, compliance frameworks, and user-friendly interfaces; DEX enables cross-chain trading and yield through smart contracts, with platforms like Hyperliquid gaining attention for their deep liquidity pools.

Both models face their own challenges: CEX faces regulatory risks and single points of failure, while DEX must address smart contract vulnerabilities and complex user experiences. The future trend points to hybrid models that combine the speed and liquidity of CEX with the autonomy and innovation of DEX. Cross-chain interoperability, atomic swaps, and liquidity aggregators are eliminating ecosystem fragmentation, paving the way for mainstream adoption.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks